Radiation Medicine Patient Registry, Loma Linda University Medical Center
NCT ID: NCT02436941
Last Updated: 2025-05-01
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
ENROLLING_BY_INVITATION
Total Enrollment
75000 participants
Study Classification
OBSERVATIONAL
Study Start Date
2003-10-20
Study Completion Date
2050-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
For most cancers, long-term follow-up is the best measure of treatment effectiveness. The Department of Radiation Medicine at Loma Linda University Medical Center operates the James M. Slater, M.D., Proton Treatment and Research Center, the world's first hospital-based proton treatment facility. Patients have been treated at the Center since 1990. Radiation treatment has been expanded and refined since the Center's opening, and these changes have been based primarily on outcomes seen and evaluated in long-term follow-up.
The Radiation Medicine Patient Registry (a multi-year database), which began as an IRB-approved study in 2003, including detailed follow-up of study data collected from 1990 and onward, is designed to track all medical information from patients treated with proton therapy and/or conventional X-ray therapy at Loma Linda University Medical Center. Information gathered from patients treated years or even decades ago helps to determine the most effective use of proton and conventional radiation in caring for patients with cancers and other diseases.
The Radiation Medicine Patient Registry (a multi-year database), which began as an IRB-approved study in 2003, including detailed follow-up of study data collected from 1990 and onward, is designed to track all medical information from patients treated with proton therapy and/or conventional X-ray therapy at Loma Linda University Medical Center. Information gathered from patients treated years or even decades ago helps to determine the most effective use of proton and conventional radiation in caring for patients with cancers and other diseases.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Proton Radiation Therapy Registry
NCT04376229
Cancer, Therapy-Related
RECRUITING
Registry Study for Radiation Therapy Outcomes
NCT01255748
Neoplasms
RECRUITING
Registry for Proton Beam Radiation Therapy
NCT02040467
Carcinoma
COMPLETED
Proton and Photon Consortium Registry (PPCR): A Multi Center Registry of Pediatric Patients Treated With Radiation Therapy
NCT01696721
Pediatric Patients Treated With Radiation Therapy
RECRUITING
Prospective Patient Registry for Radiation Oncology Techniques and Quality
NCT02368106
Solid Tumors
Cancer
WITHDRAWN
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The patient registry will be posted to accomplish three objectives:
1. Perform retrospective research studies on diseases treated with proton therapy and conventional photon radiation.
2. Maintain regular and life-long contact with patients in order to obtain current identification, contact information, and self/parent-reported health status. This information is used to generate better understanding of treatment strategies and, in turn, increase benefits to patients.
3. Enable physicians to review of medical record information and so to identify subjects who may be eligible to participate in future research studies. This requires obtaining permission from registered participants that they may be contacted and asked if they are interested in participating in studies for which they may be eligible, as determined by their medical information contained in the registry.
1. Perform retrospective research studies on diseases treated with proton therapy and conventional photon radiation.
2. Maintain regular and life-long contact with patients in order to obtain current identification, contact information, and self/parent-reported health status. This information is used to generate better understanding of treatment strategies and, in turn, increase benefits to patients.
3. Enable physicians to review of medical record information and so to identify subjects who may be eligible to participate in future research studies. This requires obtaining permission from registered participants that they may be contacted and asked if they are interested in participating in studies for which they may be eligible, as determined by their medical information contained in the registry.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Cancer
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Observational Model Type
OTHER
Study Time Perspective
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Proton or Photon
Intervention Type
RADIATION
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosis of benign or malignant tumors or other conditions deemed treatable by proton or conventional photon radiotherapy
* Willingness to sign an Informed Consent Document
* Willingness to sign an Informed Consent Document
Maximum Eligible Age
99 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Loma Linda University
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jerry D Slater, MD
Role: PRINCIPAL_INVESTIGATOR
Loma Linda University
References
Explore related publications, articles, or registry entries linked to this study.
Slater JD. Development and operation of the Loma Linda University Medical Center proton facility. Technol Cancer Res Treat. 2007 Aug;6(4 Suppl):67-72. doi: 10.1177/15330346070060S411.
Reference Type
BACKGROUND
Slater JD. Clinical applications of proton radiation treatment at Loma Linda University: review of a fifteen-year experience. Technol Cancer Res Treat. 2006 Apr;5(2):81-9. doi: 10.1177/153303460600500202.
Reference Type
BACKGROUND
Bush DA, Do S, Lum S, Garberoglio C, Mirshahidi H, Patyal B, Grove R, Slater JD. Partial breast radiation therapy with proton beam: 5-year results with cosmetic outcomes. Int J Radiat Oncol Biol Phys. 2014 Nov 1;90(3):501-5. doi: 10.1016/j.ijrobp.2014.05.1308. Epub 2014 Jul 30.
Reference Type
BACKGROUND
Slater JM, Ling TC, Slater JD, Yang GY. Palliative radiation therapy for primary gastric melanoma. J Gastrointest Oncol. 2014 Feb;5(1):E22-6. doi: 10.3978/j.issn.2078-6891.2013.057.
Reference Type
BACKGROUND
Bush DA, Cheek G, Zaheer S, Wallen J, Mirshahidi H, Katerelos A, Grove R, Slater JD. High-dose hypofractionated proton beam radiation therapy is safe and effective for central and peripheral early-stage non-small cell lung cancer: results of a 12-year experience at Loma Linda University Medical Center. Int J Radiat Oncol Biol Phys. 2013 Aug 1;86(5):964-8. doi: 10.1016/j.ijrobp.2013.05.002.
Reference Type
BACKGROUND
Ling TC, Kang JI, Bush DA, Slater JD, Yang GY. Proton therapy for hepatocellular carcinoma. Chin J Cancer Res. 2012 Dec;24(4):361-7. doi: 10.3978/j.issn.1000-9604.2012.10.09.
Reference Type
BACKGROUND
Slater JD, Loredo LN, Chung A, Bush DA, Patyal B, Johnson WD, Hsu FP, Slater JM. Fractionated proton radiotherapy for benign cavernous sinus meningiomas. Int J Radiat Oncol Biol Phys. 2012 Aug 1;83(5):e633-7. doi: 10.1016/j.ijrobp.2012.01.079.
Reference Type
BACKGROUND
Bush DA, Slater JD, Garberoglio C, Do S, Lum S, Slater JM. Partial breast irradiation delivered with proton beam: results of a phase II trial. Clin Breast Cancer. 2011 Aug;11(4):241-5. doi: 10.1016/j.clbc.2011.03.023. Epub 2011 Jun 12.
Reference Type
BACKGROUND
Coen JJ, Bae K, Zietman AL, Patel B, Shipley WU, Slater JD, Rossi CJ. Acute and late toxicity after dose escalation to 82 GyE using conformal proton radiation for localized prostate cancer: initial report of American College of Radiology Phase II study 03-12. Int J Radiat Oncol Biol Phys. 2011 Nov 15;81(4):1005-9. doi: 10.1016/j.ijrobp.2010.06.047. Epub 2010 Oct 6.
Reference Type
BACKGROUND
Talcott JA, Rossi C, Shipley WU, Clark JA, Slater JD, Niemierko A, Zietman AL. Patient-reported long-term outcomes after conventional and high-dose combined proton and photon radiation for early prostate cancer. JAMA. 2010 Mar 17;303(11):1046-53. doi: 10.1001/jama.2010.287.
Reference Type
BACKGROUND
Bush DA, Kayali Z, Grove R, Slater JD. The safety and efficacy of high-dose proton beam radiotherapy for hepatocellular carcinoma: a phase 2 prospective trial. Cancer. 2011 Jul 1;117(13):3053-9. doi: 10.1002/cncr.25809. Epub 2011 Jan 24.
Reference Type
BACKGROUND
Slater JM, Slater JD, Wroe A. Proton radiation therapy in the hospital environment: conception, development, and operation of the initial hospital-based facility, Review of Accelerator Science and Technology, Vol 2 (2009), 35-62
Reference Type
BACKGROUND
Slater JD. Twenty years of proton radiation therapy at Loma Linda University Medical Center. In U. Linz, editor. Ion beam therapy: fundamentals, technology, clinical applications. Berlin: Springer, 2012:581-595.
Reference Type
BACKGROUND
Bush DA, Smith JC, Slater JD, Volk ML, Reeves ME, Cheng J, Grove R, de Vera ME. Randomized Clinical Trial Comparing Proton Beam Radiation Therapy with Transarterial Chemoembolization for Hepatocellular Carcinoma: Results of an Interim Analysis. Int J Radiat Oncol Biol Phys. 2016 May 1;95(1):477-482. doi: 10.1016/j.ijrobp.2016.02.027. Epub 2016 Feb 13.
Reference Type
BACKGROUND
Bush DA, Slater JD, Shin BB, Cheek G, Miller DW, Slater JM. Hypofractionated proton beam radiotherapy for stage I lung cancer. Chest. 2004 Oct;126(4):1198-203. doi: 10.1378/chest.126.4.1198.
Reference Type
BACKGROUND
Slater JD, Rossi CJ Jr, Yonemoto LT, Bush DA, Jabola BR, Levy RP, Grove RI, Preston W, Slater JM. Proton therapy for prostate cancer: the initial Loma Linda University experience. Int J Radiat Oncol Biol Phys. 2004 Jun 1;59(2):348-52. doi: 10.1016/j.ijrobp.2003.10.011.
Reference Type
BACKGROUND
Bush DA, McAllister CJ, Loredo LN, Johnson WD, Slater JM, Slater JD. Fractionated proton beam radiotherapy for acoustic neuroma. Neurosurgery. 2002 Feb;50(2):270-3; discussion 273-5. doi: 10.1097/00006123-200202000-00007.
Reference Type
BACKGROUND
Slater JD, Yonemoto LT, Mantik DW, Bush DA, Preston W, Grove RI, Miller DW, Slater JM. Proton radiation for treatment of cancer of the oropharynx: early experience at Loma Linda University Medical Center using a concomitant boost technique. Int J Radiat Oncol Biol Phys. 2005 Jun 1;62(2):494-500. doi: 10.1016/j.ijrobp.2004.09.064.
Reference Type
BACKGROUND
Bush DA, Hillebrand DJ, Slater JM, Slater JD. High-dose proton beam radiotherapy of hepatocellular carcinoma: preliminary results of a phase II trial. Gastroenterology. 2004 Nov;127(5 Suppl 1):S189-93. doi: 10.1053/j.gastro.2004.09.033.
Reference Type
BACKGROUND
Bush DA, Slater JD, Bonnet R, Cheek GA, Dunbar RD, Moyers M, Slater JM. Proton-beam radiotherapy for early-stage lung cancer. Chest. 1999 Nov;116(5):1313-9. doi: 10.1378/chest.116.5.1313.
Reference Type
BACKGROUND
Slater JD, Rossi CJ Jr, Yonemoto LT, Reyes-Molyneux NJ, Bush DA, Antoine JE, Miller DW, Teichman SL, Slater JM. Conformal proton therapy for early-stage prostate cancer. Urology. 1999 May;53(5):978-84. doi: 10.1016/s0090-4295(99)00014-x.
Reference Type
BACKGROUND
Slater JD, Yonemoto LT, Rossi CJ Jr, Reyes-Molyneux NJ, Bush DA, Antoine JE, Loredo LN, Schulte RW, Teichman SL, Slater JM. Conformal proton therapy for prostate carcinoma. Int J Radiat Oncol Biol Phys. 1998 Sep 1;42(2):299-304. doi: 10.1016/s0360-3016(98)00225-9.
Reference Type
BACKGROUND
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
53191
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Proton Therapy in the Treatment of Liver Metastases
NCT01697371
RECRUITING
NA
Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
NCT06500481
RECRUITING
PHASE3
Prospective Data Registry and Quality of Life Assessment of Patients Undergoing Radiotherapy With the RefleXion Medical Radiotherapy System
NCT05406167
RECRUITING
Proton Therapy Medical Registry
NCT05151952
RECRUITING
Functional Lung Avoidance Radiation Therapy Using Hyperpolarized Xenon-129 MRI
NCT05302817
TERMINATED
PHASE1
Radiotherapy Assessments During Intervention ANd Treatment (RADIANT)
NCT03133286
COMPLETED
A Mobile Application, Oncpatient, to Assist Patients Undergoing Radiation Therapy
NCT05173961
ACTIVE_NOT_RECRUITING
NA
Feasibility, Safety, and Efficacy of Stereotactic MRI-Guided Adaptive Radiation Therapy (SMART) for Central Lung Tumors
NCT05609331
TERMINATED
NA
Proton Beam Therapy for Treatment of Hepatocellular Carcinoma
NCT00614913
COMPLETED
PHASE1/PHASE2
Mayo Clinic Radiotherapy Patient Outcomes Registry and Biobanking Study
NCT02457962
ACTIVE_NOT_RECRUITING
Patient Experience Data in Radiation Oncology
NCT05224297
RECRUITING
Registry Study to Evaluate the Clinical Outcome of Cancer Patients and Benign Diseases Treated with Radiation
NCT03617237
RECRUITING
Involved-Field Radiation Therapy in Treating Patients With Previously Untreated Stage I or Stage II Low-Grade Non-Hodgkin's Lymphoma
NCT00014326
TERMINATED
PHASE3
Selective IMRT for Locally Advanced Head and Neck Carcinoma With Concurrent Panitumumab
NCT01312493
WITHDRAWN
PHASE2
Radiation Therapy to Treat Musculoskeletal Tumors
NCT00186992
ACTIVE_NOT_RECRUITING
PHASE2
UNC Metastatic Cancer Radiation Therapy Registry
NCT06306924
RECRUITING
Hyperpolarized 129Xe Magnetic Resonance Imaging for Evaluation of Radiation-Induced Lung Injury in Subjects Undergoing Thoracic Irradiation
NCT03431129
TERMINATED
Stereotactic Body Radiation Therapy in Treating Patients With Stage I Non-Small Cell Lung Cancer
NCT00750269
COMPLETED
PHASE1/PHASE2
Clinical Registry for Oligometastic Disease, Consolidation Therapy, Debulking Prior to Chemotherapy, or Re-Irradiation
NCT02170181
COMPLETED
Registry Study of Proton Radiotherapy in Lymphoma
NCT04613388
RECRUITING
Daily Online Adaptation Versus Localization for MRI-Guided SBRT for Unresectable Primary or Oligometastatic Abdominal Malignancies
NCT02950025
TERMINATED
PHASE2
Radiation Therapy (XRT) and ZD6474 in Non-Small Cell Lung Cancer (NSCLC)
NCT00745732
TERMINATED
PHASE1
Pilot Study of Biomarkers for Radiation Therapy
NCT01050725
SUSPENDED
Biologically Guided Radiation Therapy (BgRT) and Stereotactic Body Radiation Therapy (SBRT) to Tyrosine Kinase Inhibitor in Oligoprogressive Oncogenic Positive Non-Small Cell Lung Carcinoma
NCT06014827
RECRUITING
PHASE2
Prospective Evaluation of Stereotactic Body Radiotherapy for Metastatic Prostate Cancer
NCT02206724
WITHDRAWN
NA